CMB's GMP Pilot Plant
Fraunhofer Center for Molecular Biotechnology (CMB)
The Fraunhofer USA Center for Molecular Biotechnology (CMB) is a unique institution conducting translational research in the area of pharmaceutical biotechnology, utilizing cutting-edge technologies to advance products for prevention, diagnosis and treatment of infectious diseases and autoimmune disorders. CMB, located in Newark, Delaware, is a division of Fraunhofer USA, Inc, a not-for-profit research organization.
CMB has assembled a dedicated and expert work force of over ninety full-time employees with extensive experience in research and development, GMP manufacturing, QA/QC, regulatory/clinical affairs and technology transfer. Lead scientists at the Center have published widely on recombinant protein production and are inventors on key enabling patents.
Discovering and developing innovative options for many of the worlds unmet and neglected medical needs is at the core of R&D at CMB. Our translational research focuses on targets in the vaccine, therapeutic, and antibody areas which directly relate to public health and bio-preparedness.
Our scientific staff, with expertise in diverse fields, combined with our state-of-the-art infrastructure and equipment, well positions CMB to provide R&D services including:
- Proof of Concept
- Process Development and Scale-up
- Formulation Development
- Analytical Services
- Preclinical evaluation
The partnership with the University of Delaware, a world class research institution, enhances and expands CMB’s capabilities and infrastructure.
Dr. Vidadi Yusibov, Executive Director
Fraunhofer Center for Molecular Biotechnology
9 Innovation Way
Newark, Delaware 19711
Tel: (302) 369-1708
Fax: (302) 369 8955
Parent Institute: http://www.ime.fraunhofer.de